Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $390.8 million.

  • Neurocrine Biosciences' Free Cash Flow rose 6615.65% to $390.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $748.7 million, marking a year-over-year increase of 3436.83%. This contributed to the annual value of $748.7 million for FY2025, which is 3436.83% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Free Cash Flow stood at $390.8 million, which was up 6615.65% from $214.3 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Free Cash Flow peaked at $390.8 million during Q4 2025, and registered a low of -$133.7 million during Q1 2023.
  • For the 4-year period, Neurocrine Biosciences' Free Cash Flow averaged around $134.6 million, with its median value being $119.1 million (2024).
  • Data for Neurocrine Biosciences' Free Cash Flow shows a peak YoY increase of 18908.0% (in 2024) and a maximum YoY decrease of 6932.87% (in 2024) over the last 5 years.
  • Over the past 4 years, Neurocrine Biosciences' Free Cash Flow (Quarter) stood at $82.8 million in 2021, then soared by 42.63% to $118.1 million in 2023, then soared by 99.15% to $235.2 million in 2024, then soared by 66.16% to $390.8 million in 2025.
  • Its Free Cash Flow was $390.8 million in Q4 2025, compared to $214.3 million in Q3 2025 and $89.5 million in Q2 2025.